News about Clinical Trials

Annovis Secures DSMB Nod to Advance Phase-III Buntanetap Trial in Alzheimer's

During the open session, Annovis presented an overview of the trial status, including enrollment progress, adverse events and study timelines. In the closed session, attended exclusively by DSMB voting members to ensure full objectivity and by an unblinded reporting statistician, unmasked safety data were reviewed.

Clinical Trials | 13/02/2026 | By News Bureau |  158

ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis

FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.

Clinical Trials | 12/02/2026 | By News Bureau |  123

VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002

VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.

Clinical Trials | 11/02/2026 | By News Bureau |  189

Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial

Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.

Clinical Trials | 10/02/2026 | By News Bureau |  177

Late-breaking Data Highlight Positive Safety and Closure Rates for Abbott's New Stroke-prevention Device in non-Valvular AFib

Abbott has reported positive late-breaking data from the VERITAS Study showing its Amulet 360 Left Atrial Appendage Occluder met safety and effectiveness endpoints, supporting its potential to reduce stroke risk in patients with non-valvular atrial fibrillation.

Clinical Trials | 09/02/2026 | By News Bureau |  181

Delonix Bioworks Secures NMPA IND Clearance for MenB Vaccine Candidate DX-104

China grants IND approval for DX-104 after Australia CTN clearance, paving the way for Phase I trials of Delonix’s engineered Group B meningococcal vaccine.

Clinical Trials | 09/02/2026 | By News Bureau |  226

Roche's Fenebrutinib Becomes First Investigational Therapy in Over a Decade to Slow Disability Progression in PPMS

Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.

Clinical Trials | 09/02/2026 | By News Bureau |  165

Alvotech Announces Positive Results from Pharmacokinetic Study for Entyvio

Alvotech has reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed biosimilar to Entyvio. The study met all primary endpoints, demonstrating comparable pharmacokinetics, safety, tolerability and immunogenicity to the reference product in healthy adult participants.

Clinical Trials | 06/02/2026 | By News Bureau |  110

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Clinical Trials | 04/02/2026 | By News Bureau |  287

Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress

Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.

Clinical Trials | 30/01/2026 | By News Bureau |  202